ArticleThe Pediatric infectious disease journal2026
Health and Economic Impact of Seasonal Maternal Vaccination With Bivalent Respiratory Syncytial Virus Prefusion F Vaccine in Belgium.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is the leading cause of potentially severe lower respiratory tract viral infection in infants. Hospitals may encounter challenges during the RSV season following the increased number of pediatric patients' admissions. Maternal vaccination can help address this healthcare threat. This study aimed to analyze the cost-effectiveness of the bivalent respiratory syncytial virus prefusion F-protein-based (RSVpreF) vaccine versus no immunization.
methodsA static model was developed to assess the impact of RSV-lower respiratory tract infections immunization via maternal vaccination on hospitalization, life expectancy and quality of life in an annual newborn population, from the perspective of the public healthcare payer. Key input data were derived from an independent Belgian observational study and the latest available clinical data on the bivalent RSVpreF vaccine. The targeted infants were defined based on the recommendations of the Superior Health Council for maternal vaccination.
resultsMaternal vaccination against RSV is a cost-saving option compared to no immunization against RSV, up to a cost of €183.67 (including 1 dose of vaccine and administration fee). The protection of 46,542 newborns with maternal vaccination prevented 1 infant death and 2242 pediatric hospital admissions while saving €8.57 million. These hospital savings will more than offset the cost of vaccination, resulting in incremental healthcare savings of €102,873. Moreover, in this target population, 80 QALYs will be gained over the lifetime horizon.
conclusionsThe bivalent RSVpreF vaccine, administered in line with the recommendations of the Superior Health Council, is a dominant option compared with no immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.